Addex Therapeutics Ltd (ADXN)
| Market Cap | 5.75M -12.7% |
| Revenue (ttm) | 136,508 -55.5% |
| Net Income | -8.69M |
| EPS | -0.08 |
| Shares Out | 119.32M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,105 |
| Open | 5.95 |
| Previous Close | 5.80 |
| Day's Range | 5.95 - 5.95 |
| 52-Week Range | 5.04 - 12.05 |
| Beta | 2.00 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 24, 2026 |
About ADXN
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson’s disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, ad... [Read more]
News
Addex Therapeutics (ADXN) Reveals Promising Preclinical Results on Sleep-Wake Regulation
Addex Therapeutics (ADXN) Reveals Promising Preclinical Results on Sleep-Wake Regulation
Addex Research Highlights MGlu7 Modulation As A Novel Pathway In Sleep And Stress Regulation
(RTTNews) - Addex Therapeutics (ADXN), a clinical-stage biopharmaceutical company, announced the publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric mo...
Addex Therapeutics announces publication of new ADX71743 preclinical research
Addex Therapeutics (ADXN) announced publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator of metabotropic glutamate receptor 7, significantly m...
Addex Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw strong preclinical progress in chronic cough and brain injury recovery programs, with robust efficacy and safety data. Financials showed reduced operating loss and extended cash runway, while the Neurosterix spin-out continues to advance key neuropsychiatric assets.
Addex Therapeutics Quarterly report: Q1 2026
Addex Therapeutics has published its Q1 2026 quarterly earnings report on June 25, 2026.
Addex Therapeutics Earnings release: Q1 2026
Addex Therapeutics released its Q1 2026 earnings on June 25, 2026, summarizing the period's financial results.
Addex Therapeutics Releases Q1 2026 Financial Results
Addex Therapeutics Ltd reported a dramatically narrower loss for the first quarter of 2026, as the Swiss neurological disorder specialist posted a net loss of CHF 1. The post Addex Therapeutics Releas...
Addex Records Wider Net Loss Of $1.7 Mln; Advances NTX-253 In Phase 1 For Schizophrenia
(RTTNews) - Addex Therapeutics (ADXN), a clinical-stage biopharmaceutical company, on Friday announced first quarter financial results, noting a net loss due to reduced incomes.
Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio ...
Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026
Geneva, Switzerland, June 22, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulato...
Addex Convenes Annual General Meeting 2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio o...
Addex Therapeutics Earnings Call Transcript: H2 2025
Significant pipeline progress was made in chronic cough and brain injury recovery programs, with robust preclinical results and new clinical preparations. Financials show reduced cash burn and a cash runway through mid-2026, but further funding is needed for unpartnered programs.
Addex Therapeutics Annual report: H2 2025
Addex Therapeutics has published its H2 2025 annual report on April 30, 2026.
Addex Therapeutics Earnings release: H2 2025
Addex Therapeutics released its H2 2025 earnings on April 30, 2026, summarizing the period's financial results.
Addex Therapeutics Earnings release: H2 2025
Addex Therapeutics released its H2 2025 earnings on April 30, 2026, summarizing the period's financial results.
Addex Therapeutics Annual report: H2 2025
Addex Therapeutics has published its H2 2025 annual report on April 30, 2026.
Addex Reports Full Year 2025 Financial Results and Provides Corporate Update
GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease models Continued to reposition dipraglurant mGlu5 NAM for brain injury r...
Addex Therapeutics (ADXN) Reveals Promising Preclinical Results for Chronic Cough Treatment
Addex Therapeutics (ADXN) Reveals Promising Preclinical Results for Chronic Cough Treatment
Addex Therapeutics announces GABAB PAM candidate data
Addex Therapeutics (ADXN) announced preclinical data demonstrating antitussive activity of its GABAB positive allosteric modulator candidate in a bleomycin-induced idiopathic pulmonary fibrosis exacer...
Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a por...
Addex Therapeutics (ADXN) Sees Progress with Neurosterix's Clinical Study
Addex Therapeutics (ADXN) Sees Progress with Neurosterix's Clinical Study
Addex Therapeutics says spin-out company to complete NTX-253 study in Q2
Addex Therapeutics (ADXN) announced that its spin-out company, Neurosterix, is on track to complete its Phase 1 clinical study evaluating NTX-253 in Q2. NTX-253 is an investigational potent, selective...
Addex Reports Strong Anti-Tussive For GABAB PAM Candidate
(RTTNews) - Addex Therapeutics (ADXN) has reported robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in a non-human prim...
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 21, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a por...
Addex Therapeutics Ltd – ADR trading resumes
12:01 EDT Addex Therapeutics (ADXN) Ltd – ADR trading resumes